Overview

Safety of Ertapenem in Beta-lactam Allergic Patients.

Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to at least one beta-lactam molecule.
Phase:
Phase 4
Details
Lead Sponsor:
Catholic University of the Sacred Heart
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
beta-Lactams
Ertapenem
Lactams